Apenas educação · revisão profissional necessária
Thymosin alpha-1 · Immune-research context
An immune-modulating peptide approved in some countries and not in the US.
Revisado clinicamente por Bernard Garcia, MD
O que é
Thymosin alpha-1 (Tα1) is a peptide originally isolated from thymus tissue and studied for its effects on immune cell function. It is approved as a prescription medicine in several countries (for example for chronic hepatitis B and as a vaccine adjunct) under the name Zadaxin, but it is not FDA-approved in the United States.
Interest rose sharply during the COVID-19 pandemic; the resulting trials were mixed and small.
Como funciona
Research describes effects on T-cell maturation and dendritic-cell activity. Human trials exist for specific infectious and oncology contexts abroad. General "immune support" in healthy adults has not been studied in a way that supports a claim.
Situação da pesquisa
| Área de pesquisa | Situação |
|---|---|
| Chronic hepatitis B (outside the US) | Approved in some countries |
| Oncology adjunct research | Human trials abroad, mixed |
| General immune support in healthy adults | Not established |
| Regulatory status (US FDA) | Not an FDA-approved drug |
A situação reflete apenas o contexto da pesquisa publicada e não constitui afirmação de segurança, eficácia ou adequação para qualquer pessoa.
É legal?
Thymosin alpha-1 is approved in some countries and not in the US, where it is not an FDA-approved drug. Compounded versions have faced regulatory restriction. Rules change; this is a general note, not legal advice.
Perguntas frequentes
Is thymosin alpha-1 approved anywhere?
Yes, in several countries outside the United States, for specific indications. It is not FDA-approved.
Is it the same as TB-500?
No. They are different peptides from different research areas — alpha-1 in immunology, beta-4 (TB-500) in tissue repair.
Can a US provider prescribe it?
Compounding access has been restricted by federal rule-making. A provider will explain the current position; this site does not recommend it.
Próximo passo
Próximo passo: uma triagem confidencial de 3 minutos, revisada por um profissional licenciado. Nenhum tratamento é prometido ou insinuado.
Gratuito · cerca de 10 minutos · revisado por um médico licenciado
Educação geral · Não é orientação médica · Aprovação profissional necessária